← Patent-cliff monitor small molecule QULIPTA ATOGEPANT
Loss of exclusivity February 2043 latest FDA-listed patent expiry
Company AbbVie Inc. → See this company's full patent-cliff portfolio Drug detail Brand name QULIPTA Active ingredient ATOGEPANT Strength 10MG Dosage form TABLET Route ORAL Modality Small molecule FDA approval September 2021 Marketing status RX
Listed patents Patent Expires Type 12350259 February 2043 use U-4234 12622897 September 2042 use U-4536 12465598 September 2042 use U-4355 12090148 July 2041 use U-3534 12383545 June 2039 use U-3534 8754096 September 2035 substance, product 10117836 January 2035 product 9850246 March 2033 substance 9499545 November 2031 substance, product
Regulatory exclusivity Code Expires NCE September 2026 I-909 April 2026
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.